Nursing Pharmacology Chapter 33-34: Cancer Chemotherapy Anti-Tumor Antibiotics Practice Questions
	 
	Click on the correct answer.
 
 
   
Doxorubicin clinical use(s):
-   Treatment of multiple myeloma
 -   Treatment of lymphomas
 -   Both
 -   Neither
 
 
Clinical use(s) of doxorubicin:
-   Adult sarcomas
 -   Pediatric sarcomas
 -   Both
 -   Neither
 
 
Doxorubicin administration is likely beneficial in treating osteogenic, soft-tissue sarcomas and Ewing sarcoma.
-   True
 -   False
 
 
Concerning toxic effect(s) associated with daunorubicin and doxorubicin:
-   A significant dose-limiting complication is myelosuppression.
 -   Reversible stomatitis and mucositis may occur.
 -   Doxorubicin administration may induce significant local toxicity in tissue that has been irradiated.
 -   A & B
 -   B & C
 -   A & C
 -   A, B & C
 
 
The most significant long-term toxicity due to administration of anthracyclines, e.g. daunorubicin and doxorubicin especially is cardiomyopathy.
-   True
 -   False
 
 
Factor/factors associated with enhanced risk due to anthracycline administration includes/include:
-   Myocardial radiation
 -   High-dose cyclophosphamide administration
 -   Concomitant administration of trastuzumab.
 -   A & B
 -   B & C
 -   A & C
 -   A, B & C
 
 
Epirubicin (Ellence) administration may be used as part of combination treatment of breast cancer.
-   True
 -   False
 
 
This doxorubicin analog (semisynthetic) is only used for intravesicular bladder cancer treatment.
-   Daunorubicin
 -   Idarubincin
 -   Valrubicin
 -   Mitoxantrone
 
 
Pegylated liposomal doxorubicin formulation (Doxil) clinical use/uses:
-   Treatment of AIDS-related Kaposi sarcoma
 -   Multiple myeloma
 -   Ovarian cancer
 -   A & B
 -   B & C
 -   A & C
 -   A, B & C
 
 
Daunorubicin (cerubidine):
-   Acute lymphoblastic leukemia
 -   Acute myelogenous leukemia
 -   Both
 -   Neither
 
 
		
		
            
	
		
	
		
			| 
			 
			If  
			you wish to return to the Table of Contents in ENGLISH, press 
			the RETURN button above.  | 
		
	
			 
 
	
		
			| 
			 
			Otherwise, if the text is NOT displayed in English and 
			you are ready to leave this page,
			Press here 
			to return to the Table of Contents     
			
			   |